Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of $428 million specializing in mRNA therapeutics and vaccines, stands at a ...

ARCT-032 for Cystic Fibrosis (CF): The LunairCF ... Arcturus' self-amplifying mRNA (SAM-RNA) technology represents a potential game-changer in the field of mRNA therapeutics and vaccines.

ARCT-810 for OTCD (Phase 2 data 1H '25) must prove IV dosing every 2 weeks is worth better outcomes vs. current treatments; ammonia reduction key measure of success. ARCT-032 for CF (Phase 2 data ...

In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Arcturus Therapeutics (ARCT – Research Report), with a price target of $63.00. Ed Arce has given his Buy ...

SAN DIEGO, January 10, 2025--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious ...

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Arcturus Therapeutics ARCT in the last three months. The table below summarizes their recent ...

Microsoft’s Game Pass subscription service enters 2025 bigger than ever, after finishing 2024 by adding two massive day-one blockbuster games: Call of Duty: Black Ops 6 and Indiana Jones and the ...

The company's pipeline includes ARCT-810, a treatment for ornithine transcarbamylase deficiency in Phase 2 trials, ARCT-154, a COVID-19 vaccine candidate in Phase 3 trials in Vietnam, and ARCT-032 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...